Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals ALXN - a company that is best known for its Soliris and Ultomiris drugs which are used to treat rare blood disorders - in ...

The amount is the first post-trial win for AstraZeneca subsidiary Alexion but is a fraction of the indemnification the ...

When Rachel Pegram’s adult sons were younger, she often missed their soccer games and other school functions because of her generalized myasthenia gravis (gMG), a rare autoimmune disease that causes ...

First and foremost, Alexion is healthy and profitable, with less debt on its books than it has cash. So it won't have its growth choked by indebtedness anytime soon, and can use its levered free cash ...

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune today announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a ...

As we previously reported, Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. (collectively, “Alexion”) sued Samsung Bioepis Co. Ltd. (“Samsung”) in January 2024 in the U.S ...

As federal authorities scrutinize relationships between drug makers and patient charities, Alexion Pharmaceuticals (ALXN) is the latest company to agree to settle allegations that donations amounted ...

Investors might not be overly excited about Alexion Pharmaceutical's (ALXN +0.00%) stock performance so far in 2020. But with shares trading at only 10 times expected earnings, Alexion is arguably one ...

The same day that the 2020 Resource Guide was released, the Securities and Exchange Commission (SEC) announced it had settled a Foreign Corrupt Practices Act (FCPA) enforcement action involving ...

(Reuters) -AstraZeneca's Alexion division will stop developing a treatment for the neurological disorder ALS due to lack of efficacy in a late-stage trial, the British drugmaker said on Friday. The ...

Alexion Pharmaceuticals (NASDAQ:ALXN) stock hasn’t moved much this year. But that’s not new. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased less than ...

Alexion wasn’t messing around when it set its goal for converting patients to brand-new Ultomiris, but so far, so good. The company appears to be on track to hit—perhaps even exceed—its lofty target.